Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

High blood pressure, also known as hypertension, is a major risk factor for heart disease and comes with a significant ...

Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...

and suppression of renin activity. See literature. Early treatment: initially administer three 5mg IV bolus inj given at approximately 2-minute intervals; monitor BP, HR, ECG. If full IV dose ...

The 43 patients treated with ravulizumab had a 33.2% greater reduction in average urine protein to creatinine ratio (UPCR) ...

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...

including certain antihypertensive drugs, diuretics, and NSAIDs, may be at an increased risk for kidney failure. A 2022 study conducted by researchers at the University of Waterloo and published in ...

Patients with broad range of kidney function show reduced effects following discontinuation after EMPA-KIDNEY trial.

基于优秀的循证医学证据，2024年，改善全球肾脏病预后组织（KDIGO）发布的CKD临床管理指南推荐SGLT2i作为CKD中的一线治疗药物（图3） [13] ...

h Specific for underlying mechanisms (other forms of treatment, including different antihypertensive medications = might ... which suppresses plasma renin activity These disorders should be ...

The renin-angiotensin-aldosterone system (RAAS ... If your hypertension is more advanced or lifestyle changes haven't worked for you, your healthcare provider might add one or more medications.

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in ...